RecruitingNot ApplicableNCT06027242
Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy
Sponsor
National Taiwan University Hospital
Enrollment
120 participants
Start Date
Feb 21, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.
Eligibility
Min Age: 20 Years
Inclusion Criteria1
- adult gastric cancer receiving gastrectomy
Exclusion Criteria5
- Hepatic insufficiency
- Renal insufficiency
- can not tolerate oral or enteral feeding 7 days after gastrectomy
- can not receive computed tomograph
- can not waer the wearable devices
Interventions
DIETARY_SUPPLEMENToral glutamine
10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding
DIETARY_SUPPLEMENTMaltodextrin
Maltodextrin
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06027242
Related Trials
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
NCT051871821 location
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
NCT072774391 location
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT0570222944 locations
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria
NCT074811102 locations